Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsBio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2019 American Association for Cancer Research ("AACR") Annual Meeting taking place March 2...
Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina Phase III clinical study for its tocilizumab biosimilar, BAT1806. Bio-Thera’s Phase III clinical trial will compare the safety and efficacy of BAT1806 and the reference product, Genentech’s Ro...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions Ltd (“Bio-Thera”) announced today that ithas reached a licensing agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) for BAT1706, its bevacizumab biosimilar, under which Cipla will have exclu...
